In contrast to previous studies in normophosphatemic subjects, one study attempted to investigate whether sevelamer carbonate could lower FGF23 levels in patients with CKD (Stages 3–5) and hyperphosphatemia [39]. Here, FGF23 is linked to chronic kidney disease.